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Objective: To compare the effects of tamsulosin and prazosin on clinical and urodynamic 
parameters in women with voiding dysfunction.
Methods: Forty women aged 20–65 years with a clinical diagnosis of voiding dysfunction 
were blindly randomized to two equal groups for treatment with tamsulosin 0.4 mg or 1–2 mg 
of prazosin daily. Symptom assessment with the American Urological Association Symptom 
Score (AUASS) and urodynamic evaluation was performed initially and after three months of 
treatment. Patient satisfaction was evaluated and severe adverse drug effects recorded. Statistical 
analysis was carried out using the Student’s t-test and Mann–Whitney U test.
Results: Although AUASS improved in both groups, the rate of improvement was larger in 
the tamsulosin group. Urodynamic parameters improved but did not normalize in both groups. 
Adverse side effects from medication in the prazosin group were more common than in the 
tamsulosin group. Most of the patients in the tamsulosin group (80%) were satisfied with their 
  treatment compared with those in the prazosin group (45%).
Conclusion: Tamsulosin and prazosin are both effective in palliating symptoms of women 
with voiding dysfunction and improving their urodynamic parameters. Tamsulosin may be the 
preferred drug to prescribe because of its more amenable side effect profile and greater patient 
satisfaction.
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Introduction
Women who have bladder outlet obstruction (BOO) or voiding dysfunction are 
at increased risk of developing many problems, including urine retention, urinary 
tract infections, renal insufficiency, and negative impact on quality of life. BOO is 
“the generic term for obstruction during voiding and is characterized by increased 
  detrusor pressure and reduced urine flow rate. It is usually diagnosed by studying the 
synchronous values of flow rate and detrusor pressure”.1 Factors such as age, parity, 
menopause, anticholinergic drugs, estrogen therapy, diabetes mellitus, neurological 
disorders, and pelvic surgery may contribute to the induction and aggravation of voiding 
dysfunction.2 In 1998, results from the authors’ epidemiological study in northwestern 
Iran showed that 13%–20% of females aged between 15 and 60 years suffered from 
one or more BOO symptoms.3 Despite the impact of voiding dysfunction on patients, 
relatively few treatment options have been properly investigated. Alpha-blockers are 
the first-line treatment in men with BOO due to prostate enlargement. Some recent 
studies have shown a prevalence of alpha-adrenergic receptors in the bladder neck and International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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in various regions of the female pelvic floor,4 which suggests 
that alpha-blockers may be effective in alleviating voiding 
dysfunction in women.
Clinical evaluation of the effects of alpha-blockers 
on female voiding dysfunction has not been properly 
investigated. Only a few articles published after 2002 
have demonstrated the effects of tamsulosin and   terazosin 
on   urodynamic parameters in women with voiding 
dysfunction.5–8 The aim of this study was to compare the 
effects of prazosin and tamsulosin on urodynamic findings, 
BOO symptoms, and compliance of patients with non-
neurogenic voiding dysfunction.
Methods
Between September 2005 and June 2006, 53 women aged 
20–65 years were enrolled in the study at the Women’s 
Urology Clinic of Imam Reza University Hospital, Tabriz, 
Iran. The initial screening consisted of a comprehensive 
medical history and lower urinary tract symptom assessment 
via American Urological Association Symptom Score 
(AUASS), a physical examination, and a urogynecological 
examination.
Inclusion criteria comprised voiding dysfunction   presented 
in connection with symptoms such as hesitancy, low urina-
tion flow, post-void dribbling, frequency, and   nocturia, and 
AUASS  8, maximal flow rate (Qmax)  12 mL/s, and 
post-void residual volume (PVR)  50 mL. Patients with 
a history of pelvic floor surgery during the   previous three 
months and any contraindications for   tamsolusin or prazosin 
were excluded.
Exclusion criteria eliminated an additional 13 patients 
due to spinal cord injury, severe cardiovascular disease, 
cerebrovascular disease, urine retention, indwelling cath-
eterization, anatomic outlet obstruction, renal diseases, or 
orthostatic hypotension. Forty females with AUASS  8 
were eligible for the randomized control trial (Figure 1).
Urinalysis was performed and, where indicated, a urine 
culture was taken. A complete urodynamic study, including 
a urethral pressure profile (UPP) and filling and voiding 
cystometry, was performed on all participants. UPP was 
performed in a supine position and cystometry was performed 
in a sitting position with a 10 mL/min filling pattern. Qmax, 
voided volume, PVR (by catheter), detrusor pressure at maxi-
mum flow, and urethral closure pressure were measured.
In the context of a urological examination of the hyper-
mobility of the urethra, evidence of the existence of an 
anterior or posterior pelvic organ prolapse, as defined by the 
International Continence Society (ICS), was evaluated.
Forty patients were randomly assigned to three months of 
treatment with tamsulosin 0.4 mg daily (n = 20) or prazosin 
1–2 mg daily (n = 20) in this parallel-design double-blind 
clinical trial. Distribution of the two medications in sealed, 
opaque envelopes assured masking of the treatment. Every 
month during a three-month period, patients were examined 
for symptoms and questioned about adverse effects of 
the medication. If severe adverse effects were reported, 
medication was stopped.
Questionnaire completion, the physical examination, and 
the urodynamic study were duplicated after the treatment 
course. Patient satisfaction was also evaluated on the basis 
of a three-grade scale: not satisfied, relatively satisfied, and 
completely satisfied. Adverse effects of drugs were recorded 
as reported by patients. Expected outcomes were a decrease 
in AUASS, a high level of satisfaction, and an improvement 
of urodynamic parameters.
The Student’s t-test and Mann–Whitney U test were used 
to compare differences between the groups, using SPSS for 
Windows, Version 12. A value of P  0.05 was considered 
statistically significant.
The Ethics Committee of Tabriz University of Medical 
Sciences approved the study. A verbal and written explanation 
of the study was provided for each participant, and written 
consent was obtained. The study was also registered in a 
World Health Organization authorized clinical trial registry 
(NCT00602186).
Results
A total of 40 participants aged 20–65 years participated 
in the study. Table 1 shows the background characteristics 
of the patients. There was no significant difference between 
the two groups in terms of age, family, AUASS, and pelvic 
organ prolapse.
Twenty women in each group were followed for three 
months with respect to symptom improvement and patient 
satisfaction. However, one participant from the tamsulosin 
group and two from the prazosin group did not comply with 
the control requirements of the urodynamic study.
AUASS improved in the prazosin group from 13.90 ± 6.61 
to 10.58 ± 7.64 (P  0.01). In the tamsulosin group a 
large decrease was seen from 14.65 ± 6.02 to 8.41 ± 4.23 
(P  0.01). Nine patients from the prazosin group and 
16 patients from the tamsulosin group were completely 
satisfied with treatment (P  0.05, 95% confidence interval 
1.31–11.79). The number of patients who were relatively 
satisfied in the tamsulosin group and the prazosin group 
were 1 and 4, respectively. With regard to complete patient International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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satisfaction, the absolute risk reduction of the tamsulosin 
group relative to the prazosin group was 35%. Thus, the 
resultant number needed to treat was greater than 2.8. 
  (Comparison of urodynamic data before after treatment in 
each group is given in Table 2.)
The means of urodynamic parameters before and after 
treatment in each group are shown in Table 2. PVR and 
detrusor pressure at peak flow decreased, and average flow 
rate (AFR) and peak flow rate (PFR) increased significantly 
in both groups. Figure 2 shows the percentage of normalized 
urodynamic criteria after treatment.
PVR in the tamsulosin group declined by 23.5 mL versus 
5.6 mL in the prazosin group. Adverse effects, as seen in the 
prazosin group in 13 cases, included dizziness and two cases 
of mild orthostatic hypotension, drowsiness in two patients, 
headache in five patients, and blurred vision in one patient. 
Primary outcome (patient satisfaction and 
symptom improvement) 
20 patients  
Prazosin
20 patients  
Tamsulosin
Urodynamic study
parameter improvement
18 patients 
Prazosin
19 patients 
Tamsulosin
2 ignored
Prazosin
1 ignored
Tamsulosin
Assessed for eligibility
(n = 53) 
Excluded (n = 13)
(Not meeting inclusion criteria)
Baseline assessment 
randomized (n = 40) 
Group 1 
Prazosin (n = 20)  
Group 2
Tamsulosin (n = 20) 
3 months  
Intervention
Figure 1 The Consort flowchart of patients enrolled and analyzed in the study.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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In the tamsulosin group only one patient experienced 
  drowsiness; no other side effects were noted.
Discussion
Voiding dysfunction may occur as a result of anatomical or 
neurological abnormalities of the pelvic floor.9 The purpose 
of this study was to investigate the effects of tamsulosin 
and prazosin on female voiding dysfunction. We found 
  symptom improvement in both groups, but the response rate 
of the tamsulosin group was significantly better than for the 
prazosin group, and PVR in the tamsulosin group declined 
significantly more than in the prazosin group. Fewer adverse 
effects were observed in patients who received tamsulosin 
than in those given prazosin.
Voiding dysfunction with obstructive symptoms is not 
uncommon in Iran,3 and at present there is no evidence-
based guideline for the treatment of voiding dysfunction 
or functional BOO in the country. Treating BOO has been 
shown to improve sexual function among some affected 
Iranian women.10
In terms of patient satisfaction and the detrimental 
impact of BOO symptoms on patients’ quality of life, we 
were not successful in constructing a placebo arm for the 
study design. In a pilot study in the clinic, the authors found 
symptom improvement when using 1–2 mg of prazosin daily, 
so we selected prazosin for the second arm. We believe that 
patient satisfaction and symptom improvement as subjective 
parameters and decreased PVR as an objective parameter 
are acceptable primary outcomes for patients with voiding 
dysfunction.
In a study conducted in 2005, 56% of patients with 
functional voiding dysfunction reported relative or complete 
satisfaction after 30 days of treatment.7 A significant improve-
ment was also seen in PVR, PFR, and AFR in 24 patients with 
neurogenic bladder dysfunction after one month.5
In a large series by Lee et al 84% of patients with 
non-  neurogenic voiding dysfunction were satisfied with 
tamsulosin,6 and PFR and PVR improved significantly. 
Tamsulosin also had a significant impact on urodynamic 
parameters in a study by Sivkov et al.8
Three alpha-receptor blockers (tamsulosin, alpazosin, and 
terazosin) were administered to 163 patients randomly allo-
cated to three groups in a clinical study conducted by Rossiet 
et al.13 The results indicated that tamsulosin is superior with 
respect to patient satisfaction.4
In our study the urodynamic parameters improved but 
were not normalized. Currently, there are two prevalent 
  theories regarding urodynamic parameters, ie, they may 
require more time to normalize and/or the normal range 
of these parameters may be individualized.11–13 Another 
explanation for variation in normalization of urodynamic 
parameters despite symptomatic improvement is that 
alleviation of symptoms related to urinary tract irritation 
Table 1 Comparison of the background characteristics of the 
prazosin and tamsulosin groups
Tamsulosin  
group
Prazosin  
group
Mean age (years ± standard deviation)  47.35 ± 15.50 49.4 ± 13.27
Number of patients with mild  
to moderate symptoms (AUASS)
15 16
Number of patients with severe  
symptoms (AUASS)
5 4
Number of patients with rectocele 9 8
Number of patients with cystocele 11 10
Number of patients with vaginal atrophy 4 5
Parity = 0 1 2
Parity = 1–3 10 9
Parity 3 8 8
Unknown 1 1
Number of postmenopause patients 8 7
Abbreviation: AUASS, American Urology Association Symptom Score.
Table 2 Comparison of urodynamic data before and after treatment in the prazosin and tamsulosin groups
Urodynamic test Treatment 
group
Before 
treatment
After 
treatment
Confidence 
interval
P
PVR (mL) Prazosin 106.85 ± 51.92 100.88 ± 54.76 1.41–19.47 0.01
Tamsulosin 111.11 ± 145.95 121.50 ± 102.02 12.62–36.27 0.01
Average flow rate (mL/s) Prazosin 7.15 ± 3.03 7.20 ± 306 -0.80–(-0.18) 0.01
Tamsulosin 4.71 ± 1.80 5.42 ± 1.74 -0.98–(-0.43) 0.01
Qmax (mL/s) Prazosin 9.24 ± 3.86 10.47 ± 5.14 -2.77–(-0.64) 0.01
Tamsulosin 9.27 ± 4.67 10.68 ± 4.86 -2.19–(-0.62) 0.01
Urethral closure pressure (cmH2O) Prazosin 147.16 ± 22.59 117.05 ± 19.34 26.35–36.64 0.01
Tamsulosin 147.10 ± 16.06 120.90 ± 19.82 21.17–31.22 0.01
Pressure at Qmax (cmH2O) Prazosin 39.01 ± 13.83 36.26 ± 14.10 -2.90–(-1.01) 0.01
Tamsulosin 47.07 ± 17.25 44.33 ± 17.63 -03.88–(-1.58) 0.01
Abbreviations: PVR, post-void residual volume; Qmax, maximal flow rate.International Journal of General Medicine
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and BOO is mediated by alpha-1D receptor blockade. This 
phenomenon may be independent from drug impact on uro-
dynamic parameters.14
The three-month follow-up of patients is one of the 
strengths of the study. The effects of tamsulosin are 
  evidenced extensively in benign prostates,15,16 but very few 
studies have been done on female non-neurogenic voiding 
dysfunction. The results of this investigation may help to 
provide an effective clinical guideline for medical treatment 
of non-neurogenic voiding dysfunction or functional BOO 
in females.
In conclusion, both tamsulosin and prazosin may be effec-
tive in palliating symptoms of women with voiding dysfunc-
tion and improve their urodynamic parameters (but not their 
normalization). Although neither of these two medications is 
superior with regard to urodynamic changes, tamsulosin is 
preferred because of its more acceptable side effect profile 
and higher level of patient satisfaction.
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prazosin and tamsulosin trial groups.
Abbreviations: PVR, post-void residual volume; Qmax, maximal flow rate.